Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 188-193, Summer 2009

Making the Case for Molecular Staging of Malignant Pleural Mesothelioma

  • Raphael Bueno, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Raphael Bueno, MD, Division of Thoracic Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115

Division of Thoracic Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts

Malignant pleural mesothelioma is an aggressive malignancy for which surgical treatment is an option for a subset of patients. A gene ratio test based on the relative expression levels of four genes has been validated in clinical trials to predict which patients will benefit from surgical therapy. A description of the test properties and the independent predictors for outcome are provided.

Keywords: mesothelioma, predictive test, gene ratio test, RNA expression, outcome in mesothelioma, staging of mesothelioma, surgery in mesothelioma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1043-0679(09)00078-1

doi:10.1053/j.semtcvs.2009.07.003

Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 188-193, Summer 2009

Article Tools

* Image Usage & Resolution